Randomized trial · people
Semaglutide: 24% lower risk of major kidney events in FLOW
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with type 2 diabetes and chronic kidney disease, this large trial links semaglutide to fewer serious kidney events and fewer deaths from heart causes than placebo over a median of 3.4 years.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 3533
- Published
- 2024
- Journal
- N Engl J Med
What they tested
The team tested whether weekly semaglutide lowers the risk of kidney failure, heart-related death and other serious outcomes in people with both type 2 diabetes and chronic kidney disease.
How the study was done
A randomized, placebo-controlled trial in 3533 people with type 2 diabetes and chronic kidney disease, who got either a 1.0 mg weekly semaglutide shot under the skin or placebo (a dummy shot). Median follow-up was 3.4 years, and the trial was stopped early on the advice given at a planned interim analysis.

Model. Individual results vary.
What they found
The main outcome combined kidney failure, a drop of at least 50% in eGFR (an estimate of how well the kidneys filter blood), and death from kidney or heart causes. It happened 331 times in the semaglutide group and 410 times in the placebo group, a 24% lower risk (hazard ratio 0.76; 95% CI 0.66 to 0.88). Death from heart and blood vessel causes was also lower (hazard ratio 0.71), as were major cardiovascular events (hazard ratio 0.82) and death from any cause (hazard ratio 0.80). eGFR fell more slowly each year with semaglutide, by 1.16 ml per minute per 1.73 m2, and serious side effects were reported in 49.6% of the semaglutide group versus 53.8% of the placebo group.
What it doesn’t show
The trial included only people with type 2 diabetes and chronic kidney disease within set eGFR and urine albumin ranges, tested a single 1.0 mg dose, and was stopped early. It was funded by Novo Nordisk.
The paper
Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.